Compare Nerdwallet Inc (NRDS) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs Recursion Pharmaceuticals Inc — how do they compare? Nerdwallet Inc trades at $9.91 (market cap $625.17M), while Recursion Pharmaceuticals Inc trades at $3.99 (market cap $2.14B). The key difference: Recursion Pharmaceuticals Inc is far larger — about 3.4× Nerdwallet Inc's market cap, and Recursion Pharmaceuticals Inc is more actively traded (30,789,535 versus 1,321,316). Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and Recursion Pharmaceuticals Inc for 22 Days on average.
| NRDS | RXRX | |
|---|---|---|
Market Cap | $625.17M | $2.14B |
Volume | 1,321,316 | 30,789,535 |
Sector | Media | Health |
52-Week High | $15.93 | $6.79 |
52-Week Low | $7.58 | $2.84 |
Typical Hold Time | 45 Days | 22 Days |
Enterprise Value | $539.47M | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.085, up 2.54% with bullish technical indicators and strong fundamental momentum. The company shows impressive revenue growth from $539M in 2022 to $837M in 2025, with net income turning positive to $48.7M. Recent Q2 2026 earnings missed expectations at $0.07 per share versus $0.0934 expected, but Q1 and Q4 2025 beat estimates. Analyst consensus remains positive with 4 buy ratings out of 6, and technical analysis shows bullish signals across moving averages and oscillators.
Outlook remains favorable with projected 2026 revenue of $860M and net income of $65M, though Q2 earnings miss and high RSI suggest near-term caution. The stock offers attractive valuation with P/E of 10.87 and P/S of 0.81, but faces risks from organic search pressure in key product categories and macroeconomic sensitivity.
RXRX trades at $4.27, down 7.78% today, with technical indicators showing a bullish trend despite recent weakness. The company reported Q2 2026 earnings miss after two consecutive beats, with revenue declining to $54 million in 2026 from $74 million in 2025. While maintaining a negative net income margin of -961.97%, RXRX continues to expand its AI-powered drug discovery platform through strategic partnerships with Tempus and Roche.
The stock presents high-risk growth potential with strong analyst support (40% buy rating) but faces significant execution challenges. Investment appeal hinges on successful pipeline development and commercialization of AI drug discovery technology, though persistent losses and declining revenue create substantial downside risk for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
